Business
CareDx Announces Landmark KOAR Study Published in the American Journal of Transplantation
KOAR, the Largest Prospective Study of Its Kind, Demonstrates Clinical Utility of AlloSure® in Kidney Transplant Surveillance AlloSure Kidney dd-cfDNA
About this update from Caredx, Inc.
KOAR, the Largest Prospective Study of Its Kind, Demonstrates Clinical Utility of AlloSure® in Kidney Transplant Surveillance AlloSure Kidney dd-cfDNA Elevation Strongly Predicts Rejection and Improves Biopsy Yield BRISBANE, Calif. --(BUSINESS WIRE)-- CareDx, Inc. (Nasdaq: CDNA), — The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced the publication of the Kidney Allograft Outcomes AlloSure Registry (KOAR) study in the American Journal of Transplantation . The landmark prospective study demonstrates the clinical utility of AlloSure® donor-derived cell-free DNA (dd-cfDNA) in improving rejection detection and guiding biopsy decisions in kidney transplant recipients. The KOAR study enrolled 1,743 patients across 56 U.S. transplant centers to evaluate the clinical utility of a dd-cfDNA surveillance protocol based on the DART study, which prescribed seven tests in year one and four annually in years two and three. A total of 18,584 AlloSure tests were obtained from the overall cohort. “The scale and clarity of KOAR make it a landmark,” said Daniel C. Brennan , MD, Professor of Medicine at Johns Hopkins , author of the publication, and the senior author of the primary DART publication. “In fact, it shows that dd-cfDNA should be considered the first-line test even before DSA. It’s arguably the most powerful biomarker we have in kidney transplantation today.” “KOAR confirms that dd-cfDNA is a clinically actionable tool that enhances how we detect and manage rejection,” said Jonathan S. Bromberg , MD, PhD, Professor of Surgery at the University of Maryland , lead author of the publication, and a key author on the DART publications. “Importantly, it helps clinicians tailor care based on risk.” Key findings include: Elevated AlloSure was associated with a 6-fold increase in rejection yield in surveillance biopsies (39% vs. 7%, p